# Stayble Therapeutics > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/staybletherapeutics). ## Overview Stayble Therapeutics AB is a Swedish clinical-stage biopharmaceutical company based in Gothenburg. It develops STA363, an injectable treatment concept for pain caused by herniated disc, with the aim of addressing the underlying cause of symptoms rather than only providing temporary relief. ## Products & services • STA363 injectable treatment for disc-related pain • Clinical development of a drug candidate based on an existing substance • Phase 1b study execution and clinical data generation • Future licensing and commercialization of the treatment concept - **Drug candidate development** (100%) — Development of STA363 as a treatment for pain caused by herniated disc. - **Clinical research and trials** (0%) — Clinical study work to test safety, efficacy, and dosing of the candidate. - **Licensing and commercialization rights** (0%) — Potential future out-licensing or partnering of the treatment concept. - STA363 injectable treatment for disc-related pain - Clinical development of a drug candidate based on an existing substance - Phase 1b study execution and clinical data generation - Future licensing and commercialization of the treatment concept ## Customers Stayble does not appear to sell a commercial product yet; its near-term counterparties are clinical trial participants, investigators, and development partners. In a future commercial model, the end users would be patients with persistent pain after disc herniation, while buyers would likely include healthcare providers, hospitals, and potentially licensed pharmaceutical partners. - **Clinical trial participants** (primary) — Patients enrolled to evaluate STA363 safety and efficacy in disc-related pain. - **Clinical investigators and trial sites** (primary) — Hospitals and research centers that administer the study protocol and collect data. - **Potential licensing partners** (secondary) — Pharmaceutical or biotech companies that may acquire rights to develop or commercialize STA363. - **Future treating physicians and clinics** (emerging) — Healthcare providers that would prescribe or administer the treatment if approved. - Clinical trial patients with persistent disc-related pain - Investigators and trial sites running the studies - Potential pharmaceutical licensees or development partners - Future healthcare providers treating herniated disc pain - Payers and providers that would adopt the therapy if approved ## Geography Stayble is headquartered in Gothenburg, Sweden, and its corporate and development activities are anchored there. The available reports do not disclose a commercial revenue geography, which is consistent with a development-stage company whose operations are centered on Sweden and external clinical development partners. - Headquartered in Gothenburg, Sweden - Corporate and development functions are based in Sweden - No disclosed commercial revenue geography in the provided reports - Clinical development depends on external trial locations and partners ## Strategy Stayble’s strategy is centered on advancing STA363 through clinical development and building evidence that the treatment can address disc-related pain with a simple, one-time injection. The company also emphasizes using an existing active substance, which can shorten development timelines and support future partnering or licensing discussions. - **Advance clinical development of STA363** (short-term) — Clinical data is the main value driver for a pre-commercial biotech company. - **Differentiate with a one-time injection concept** (medium-term) — A simple treatment profile can improve adoption and partnering appeal. - **Prepare for partnering or commercialization** (medium-term) — External partners may be needed to fund late-stage development and market access. - Advance STA363 through clinical development - Build clinical evidence for disc-related pain treatment - Use an existing substance to reduce development complexity - Position the asset for future partnering or licensing - Focus on a one-time injection with durable effect ## Risks Stayble is exposed to the classic risks of a clinical-stage biotech company: funding needs, uncertain trial outcomes, and dependence on third-party development partners. Because it does not yet generate product sales, setbacks in clinical development or capital raising could materially affect its ability to continue operations. - **Financing risk** [critical] — The company has no approved treatment generating sales and must fund ongoing development. - **Clinical trial risk** [high] — Drug development depends on proving safety and efficacy in human studies. - **Partner dependency risk** [high] — Development and future commercialization may rely on external collaborators. - **Regulatory approval risk** [high] — Even promising clinical data may not translate into marketing authorization. - No approved product means no operating sales base - Clinical trial results may fail to show safety or efficacy - Funding risk is high because development is capital intensive - Dependence on partners can delay development or execution - Regulatory approval remains uncertain even after positive data ## Accounting As a development-stage biotech, Stayble’s reported results are likely driven by expensed research and development, personnel costs, and external study services rather than product revenue. Investors should also watch estimates around going concern, accruals for clinical and advisory services, and any impairment or capitalization judgments tied to development assets. - **Research and development expense recognition** — Affects operating result and comparability across periods - **Accruals for clinical trial and advisory costs** — Can shift expenses between quarters - **Going concern and liquidity assumptions** — Affects disclosure and valuation of the business - **Impairment and capitalization judgments** — Can materially affect balance sheet and earnings - Research and development costs likely dominate the income statement - Clinical accruals depend on timing of trial services and invoices - Going concern assessment is important for a pre-revenue company - Any development asset judgments can affect impairment testing - Lease accounting may matter for office and headquarters costs --- *Last updated: 2026-08-11T04:04:55.958844+00:00*